Cannabix Technologies Granted U.S. Patent - Cannabis Drug Detection Device

Vancouver, British Columbia, January 12, 2021 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company. The Company and its patent attorneys have been pursuing this patent application since its filing in 2014.  Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.
 
“The intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2014. Considering the field of breath detection of drugs is in its infancy, this patent is a useful step in our IP protection strategy” said Dr. Raj Attariwala.
 
In light of the granting of U.S. patent 14/689434, the Company undertaken a strategic review of its existing patent applications and will re-align its portfolio by canceling its second license agreement with the University of Florida (UF) in relation to patent application 16/082,220. The Company will continue with its original license agreement with UF in relation to patent 8,237,118.
 
As a requirement under the license agreement between the Company and Cannabix Breathalyzer Inc. (a separate entity) entered into on June 5th, 2014, Company will issue 5 million common shares to Cannabix Breathalyzer Inc. as a final milestone payment, triggered by the grant of patent 14/689434 by the USPTO.